Identification and validation of TGFBI as a promising prognosis marker of clear cell renal cell carcinoma
Authors:
- 1 February 2015
- journal article
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 33 (2) , 69.e11-69.e18
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Quantitative proteomic determination of diethylstilbestrol action on prostate cancerAsian Journal of Andrology, 2013
- Quantitative Proteomic Analysis in Metastatic Renal Cell Carcinoma Reveals a Unique Set of Proteins with Potential Prognostic SignificanceMolecular & Cellular Proteomics, 2013
- EAU Guidelines on Renal Cell Carcinoma: The 2010 UpdateEuropean Urology, 2010
- External Validation of the Mayo Clinic Stage, Size, Grade, and Necrosis (SSIGN) Score for Clear-Cell Renal Cell Carcinoma in a Single European Centre Applying Routine PathologyEuropean Urology, 2010
- iTRAQ proteomic identification of pVHL-dependent and -independent targets of Egln1 prolyl hydroxylase knockdown in renal carcinoma cellsAdvances in Enzyme Regulation, 2009
- Differential Protein Expressions in Renal Cell Carcinoma: New Biomarker Discovery by Mass SpectrometryJournal of Proteome Research, 2009
- Challenges of Cancer Biomarker ProfilingEuropean Urology, 2007
- Vascular Endothelial Growth Factor–Targeted Therapy in Renal Cell Carcinoma: Current Status and Future DirectionsClinical Cancer Research, 2007
- Technical, Experimental, and Biological Variations in Isobaric Tags for Relative and Absolute Quantitation (iTRAQ)Journal of Proteome Research, 2007
- Prognostic value of uPA, PAI-1, and dna content in adult renal cell carcinomaUrology, 2004